All In Biotech

Drug Trial Radar · NCT07802704

A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]

A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan, a B7-H3 Antibody Drug Conjugate (ADC) in Participants With Metastatic Castration-resistant Prostate Cancer (EMBOLD Prostate-302)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 684 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

684

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Dec 5, 2029

Study completion Dec 5, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.

Conditions

  • Neoplasms, Prostate

Interventions

  • Risvutatug rezetecan (Ris-Rez)Biological

    Risvutatug rezetecan (Ris-Rez) will be administered.

  • EnzalutamideDrug

    Enzalutamide will be administered.

  • AbirateroneDrug

    Abiraterone will be administered.

  • PrednisoneDrug

    Prednisone will be administered along with Abiraterone.

  • PrednisoloneDrug

    Prednisolone will be administered along with Abiraterone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-Free Survival (rPFS) per PCWG3 by BICRTime frame: Up to approximately 169 weeks
  2. Overall Survival (OS)Time frame: Up to approximately 169 weeks

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Auchenflower, Queensland, Australia · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tottori, Japan · Recruiting

  • GSK Investigational Site

    Gyeonggi-do, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.